Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson’s disease
- 30 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Glycoconjugate Journal
- Vol. 39 (1), 1-11
- https://doi.org/10.1007/s10719-021-10012-0
Abstract
Parkinson’s disease (PD) is a major neurodegenerative disorder which exhibits many of the characteristics of a pandemic. Current therapeutic strategies are centered on the dopaminergic system, with limited efficacy, so that a treatment that has a direct impact on the underlying disease pathogenesis is urgently needed. Although α-synuclein is a privileged target for such therapies, this protein has been in the past wrongly considered as exclusively intracellular, so that the impact of paracrine neurotoxicity mechanisms in PD have been largely ignored. In this article we review the data showing that lipid rafts act as plasma membrane machineries for the formation of α-synuclein pore-like oligomers which trigger an increase of intracellular Ca2+. This Ca2+ influx is responsible for a self-sustained cascade of neurotoxic events, including mitochondrial oxidative stress, tau phosphorylation, Ca2+ release from the endoplasmic reticulum, Lewy body formation, and extracellular release of α-synuclein in exosomes. The first step of this cascade is the binding of α-synuclein to lipid raft gangliosides, suggesting that PD should be considered as both a proteinopathy and a ganglioside membrane disorder lipidopathy. Accordingly, blocking α-synuclein-ganglioside interactions should annihilate the whole neurotoxic cascade and stop disease progression. A pipeline of anti-oligomer molecules is under development, among which an in-silico designed synthetic peptide AmyP53 which is the first drug targeting gangliosides and thus able to prevent the formation of α-synuclein oligomers and all downstream neurotoxicity. These new therapeutic avenues challenge the current symptomatic approaches by finally targeting the root cause of PD through a long-awaited paradigm shift.Keywords
This publication has 120 references indexed in Scilit:
- Exosomal cell-to-cell transmission of alpha synuclein oligomersMolecular Neurodegeneration, 2012
- Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by α-Synuclein Oligomers in Lipid MembranesPLOS ONE, 2012
- Assessment of α-Synuclein Secretion in Mouse and Human Brain ParenchymaPLOS ONE, 2011
- In vivo demonstration that α-synuclein oligomers are toxicProceedings of the National Academy of Sciences of the United States of America, 2011
- Elevated Levels of α-Synuclein Oligomer in the Cerebrospinal Fluid of Drug-Naïve Patients with Parkinson's DiseaseJournal of Clinical Neurology, 2011
- Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicityThe FASEB Journal, 2010
- Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseasesExpert Reviews in Molecular Medicine, 2010
- Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after EndocytosisNeuron, 2010
- Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinementProceedings of the National Academy of Sciences of the United States of America, 2008
- Helical α-Synuclein Forms Highly Conductive Ion ChannelsBiochemistry, 2007